Mycophenolate mofetil and prednisolone for cerebral sinus venous thrombosis with Behcet's disease
Corresponding Author
Shintaro Terashita
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Department of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan
Correspondence: Shintaro Terashita, MD, Department of Pediatrics, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama City, Toyama 930-0194, Japan. Email: [email protected]Search for more papers by this authorTomomi Tanaka
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Search for more papers by this authorHiromichi Taneichi
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Search for more papers by this authorYuichi Adachi
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Search for more papers by this authorMasaaki Mori
Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Shintaro Terashita
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Department of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan
Correspondence: Shintaro Terashita, MD, Department of Pediatrics, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama City, Toyama 930-0194, Japan. Email: [email protected]Search for more papers by this authorTomomi Tanaka
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Search for more papers by this authorHiromichi Taneichi
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Search for more papers by this authorYuichi Adachi
Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan
Search for more papers by this authorMasaaki Mori
Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this author
References
- 1Koné-Paut I, Shahram F, Darce-bello M et al. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Ann. Rheum. Dis. 2016; 75: 958–64.
- 2Seyahi E. Behçet's disease: How to diagnose and treat vascular involvement. Best Pract. Res. Clin. Rheumatol. 2016; 30: 279–95.
- 3Sato T, Takagawa T, Kakuta Y et al. NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases. Intest. Res. 2017; 15: 328–37.
- 4Viswanathan V, Murray KJ. Management of children with juvenile idiopathic arthritis. Indian J. Pediatr. 2016; 83: 63–70.
- 5Shugaiv E, Tüzün E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: Presentation of four cases. Clin. Exp. Rheumatol. 2011; 29: S64–7.
- 6Groot N, de Graeff N, Marks SD et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann. Rheum. Dis. 2017; 76: 1965–73.
- 7Li S, Yang H, Guo P et al. Efficacy and safety of immunosuppressive medications for steroid-resistant nephrotic syndrome in children: A systematic review and network meta-analysis. Oncotarget 2017; 8: 73050–62.
Citing Literature
